(Reuters) – The U.S. Food and Drug Administration has approved Impel NeuroPharma Inc’s intranasal spray to treat acute migraine, the drug developer said on Friday.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Ramakrishnan M.)
U.S. FDA approves Impel NeuroPharma’s acute migraine treatment
Sep 3, 2021 | 7:55 AM
